ADCs are a new class of cancer therapies designed to precisely target and kill tumour cells while sparing healthy ones.
Ovarian cancer is the leading cause of death from gynaecological cancers in the US, and approximately 20,000 patients are diagnosed with the disease each year.
Positive results from the late-stage MIRASOL confirmatory trial will support a supplemental Biologic License Application submission to the FDA in order to gain full approval for Elahere, as well as an application for use of the drug in the EU.
Ongoing clinical development programmes are also underway to expand into earlier lines of therapy and enter other large patient segments of the ovarian market over the next five to ten years, AbbVie added.
Richard Gonzalez, chairman and chief executive officer, AbbVie, said the acquisition enables the company to "further diversify [its] oncology pipeline across solid tumours and haematologic malignancies”.
"Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer,” he said.
Mark Enyedy, president and chief executive officer, ImmunoGen, said: "With global commercial infrastructure and deep clinical and regulatory expertise, AbbVie is the right company to accelerate geographic and label expansion and realise the full potential of Elahere as the first and only ADC approved in ovarian cancer.
"The addition of ImmunoGen's pipeline, platform and expertise to AbbVie's oncology portfolio is an exciting opportunity for the combined companies to advance innovation in ADCs.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.